{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:58:12Z","timestamp":1790017092490,"version":"4.0.1"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In the phase 3 PROpel trial (NCT03732820) patients with metastatic castration\u2010resistant prostate cancer (mCRPC) treated with olaparib plus abiraterone in the first\u2010line setting showed significantly prolonged radiographic progression\u2010free survival (rPFS; primary data cutoff [DCO]: 30 July 2021; hazard ratio [HR] 0.66, 95% confidence interval [CI], 0.54\u20130.81; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and at prespecified final OS analysis DCO (12 October 2022) numerically prolonged overall survival (OS; HR 0.81, 95% CI, 0.67\u20131.00; <jats:italic>p<\/jats:italic>\u2009=\u20090.054), versus placebo plus abiraterone for the global population. Here, we report efficacy, safety, and patient\u2010reported outcome data for the Asian subset in PROpel. Eligible patients were randomly assigned (1:1) to either olaparib (300\u2009mg twice daily) or placebo in combination with abiraterone (1000\u2009mg once daily). The primary endpoint was investigator\u2010assessed rPFS, and a key secondary endpoint was OS. In the Asian subset (<jats:italic>n<\/jats:italic>\u2009=\u2009133) at primary analysis, median rPFS was 27.6\u2009months in the olaparib plus abiraterone arm (<jats:italic>n<\/jats:italic>\u2009=\u200963), compared with 19.3\u2009months in the placebo plus abiraterone arm (<jats:italic>n<\/jats:italic>\u2009=\u200970; HR 0.55, 95% CI, 0.32\u20130.95). Median OS at the final analysis was not reached in the olaparib plus abiraterone arm versus 43.7\u2009months in the placebo plus abiraterone arm (HR 0.59, 95% CI, 0.32\u20131.06). The safety profile was generally similar in the Asian subset and the global population. Efficacy and safety results for olaparib plus abiraterone in the Asian subset were generally consistent with the global PROpel population supporting the combination of olaparib plus abiraterone as an important first\u2010line treatment for consideration in Asian patients with mCRPC.<\/jats:p><jats:p><jats:bold>Trial Registration:<\/jats:bold> <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link> identifier: NCT03732820<\/jats:p>","DOI":"10.1111\/cas.16459","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:15:34Z","timestamp":1742296534000},"page":"1638-1647","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration\u2010Resistant Prostate Cancer: <scp>PROpel<\/scp> Subset Analysis"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-4263","authenticated-orcid":false,"given":"Mototsugu","family":"Oya","sequence":"first","affiliation":[{"name":"Keio University Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Young","family":"Joung","sequence":"additional","affiliation":[{"name":"Center for Prostate Cancer National Cancer Center  Goyang South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Youl","family":"Lee","sequence":"additional","affiliation":[{"name":"Seoul St Mary's Hospital The Catholic University of Korea  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-782X","authenticated-orcid":false,"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Kagawa University Hospital  Kagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Deuk","family":"Choi","sequence":"additional","affiliation":[{"name":"Yonsei University College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hyuk","family":"Hong","sequence":"additional","affiliation":[{"name":"Asan Medical Center University of Ulsan College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[{"name":"Yokohama City University Medical Center  Yokohama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Osaka International Cancer Institute  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyasu","family":"Tsumura","sequence":"additional","affiliation":[{"name":"Kitasato University School of Medicine  Sagamihara Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Saitama Medical Center Saitama Medical University  Kawagoe Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"Hirayama","sequence":"additional","affiliation":[{"name":"Osaka Metropolitan University Graduate School of Medicine  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Gyun","family":"Kwon","sequence":"additional","affiliation":[{"name":"Chilgok Kyungpook National University Medical Center  Daegu South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol","family":"Kwak","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital Seoul National University College of Medicine  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Toho University Sakura Medical Center  Chiba Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Fujita","sequence":"additional","affiliation":[{"name":"AstraZeneca  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nii","sequence":"additional","affiliation":[{"name":"AstraZeneca  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McGuinness","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Dujka","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Poehlein","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Clarke","sequence":"additional","affiliation":[{"name":"The Christie and Salford Royal Hospital NHS Foundation Trusts and University of Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71205-7"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.061"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa003"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00206"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30365-6"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00382-0"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01649"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01055-3"},{"key":"e_1_2_11_11_1","unstructured":"European Medicines Agency \u201cLynparza Summary of Product Characteristics \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/lynparza\u2010epar\u2010product\u2010information_en.pdf(2024)."},{"key":"e_1_2_11_12_1","unstructured":"US Food & Drug Administration \u201cLynparza\u00ae Prescribing Information \u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s025lbl.pdf(2024)."},{"key":"e_1_2_11_13_1","unstructured":"AstraZeneca \u201cLynparza Plus Abiraterone Approved in Japan for the Treatment of BRCA\u2010Mutated Metastatic Castration\u2010Resistant Prostate Cancer \u201d2023."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00409.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12647"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34608"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12826"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2013.54.1.1"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020407"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017748"},{"key":"e_1_2_11_21_1","unstructured":"US Food & Drug Administration \u201cZYTIGA\u00ae Prescribing Information \u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202379lbl.pdf(2024)."}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.16459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T02:06:06Z","timestamp":1748829966000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.16459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/cas.16459"],"URL":"https:\/\/doi.org\/10.1111\/cas.16459","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"2024-07-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}